T2DM is associated with low-grade systemic inflammation, and increased NF-κB DNA binding activity was found to be one of the characteristics of muscle tissue from T2DM patients [96], in agreement with suggestions that the NF-κB pathway may represent a therapeutic target for insulin resistance [97]. The gene discussed is NFKB1; the disease is Insulin resistance.